Indicated for: non-small cell lung cancer
Route of administration: injectable
Substance: pemetrexeda (antimetabolite antineoplastic)
ATC: L01BA04 (Antineoplastic and immunomodulating agents | Antimetabolites | Folic acid analogues)
This medicine may affect fertility.
Dose adjustment may be needed in liver disease.
Handle with special care.
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
This medicine may affect the liver.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
This medicine is subject to additional monitoring.
Periodic laboratory tests may be required during treatment.
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Pemetrexed is a chemotherapy agent used in the treatment of lung cancer and malignant pleural mesothelioma. It works by inhibiting enzymes involved in DNA and RNA synthesis, thereby preventing tumor cell growth.
The medication is administered intravenously, as directed by a doctor, usually once every three weeks. It is important for patients to follow the treatment regimen and take folic acid and vitamin B12 supplements to reduce the risk of side effects.
Patients should be aware of potential side effects, such as fatigue, nausea, or decreased blood cell counts. It is important to inform the doctor of any unusual symptoms.
Common side effects include fatigue, nausea, and anemia. In rare cases, severe reactions such as hematologic toxicity or allergic reactions may occur. Patients should be informed of these risks before use.